Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease
Open Access
- 18 December 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 5 (2) , 186-191
Abstract
An important stage in the development of any new therapeutic agent is establishment of the optimal dosage and route of administration. This can be particularly challenging when the treatment is a biologic agent that might exert its therapeutic effects via complex or poorly understood mechanisms. Multiple preclinical and clinical studies have shown paradoxical results, with inconsistent findings regarding the relationship between the cell dose and clinical benefit. Such phenomena can, at least in part, be attributed to variations in cell dosing or concentration and the route of administration (ROA). Although clinical trials of cell-based therapy for cardiovascular disease began more than a decade ago, specification of the optimal dosage and ROA has not been established. The present review summarizes what has been learned regarding the optimal cell dosage and ROA from preclinical and clinical studies of stem cell therapy for heart disease and offers a perspective on future directions.Significance: Preclinical and clinical studies on cell-based therapy for cardiovascular disease have shown inconsistent results, in part because of variations in study-specific dosages and/or routes of administration (ROA). Future preclinical studies and smaller clinical trials implementing cell-dose and ROA comparisons are warranted before proceeding to pivotal trials.Keywords
Funding Information
- National Institutes of Health (UM1HL113460, R01 HL084275, R01 HL110737, 5UM1HL087318)
This publication has 42 references indexed in Scilit:
- Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic CardiomyopathyJAMA, 2014
- Comparison of Transendocardial and Intracoronary CD34 + Cell Transplantation in Patients With Nonischemic Dilated CardiomyopathyCirculation, 2013
- Durable Scar Size Reduction Due to Allogeneic Mesenchymal Stem Cell Therapy Regulates Whole‐Chamber RemodelingJournal of the American Heart Association, 2013
- Enhanced Effect of Combining Human Cardiac Stem Cells and Bone Marrow Mesenchymal Stem Cells to Reduce Infarct Size and to Restore Cardiac Function After Myocardial InfarctionCirculation, 2013
- Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart FailureJAMA, 2012
- Intramyocardial, Autologous CD34+ Cell Therapy for Refractory AnginaCirculation Research, 2011
- Intramyocardial Stem Cell Injection in Patients With Ischemic CardiomyopathyCirculation Research, 2011
- Bone Marrow Mesenchymal Stem Cells Stimulate Cardiac Stem Cell Proliferation and DifferentiationCirculation Research, 2010
- Effects of Adipose Tissue-Derived Stem Cell Therapy After Myocardial Infarction: Impact of the Route of AdministrationJournal of Cardiac Failure, 2010
- Mesenchymal Cell Transplantation and Myocardial Remodeling After Myocardial InfarctionCirculation, 2009